Overzicht longkankerstudies in Nederland

Op deze pagina vindt u de lopende longkankerstudies van de aangesloten centra. Maak gebruik van de zoek- en filterfunctie om eenvoudig door het aanbod van de lopende longkankerstudies te navigeren.

1479.0001 BI (Beamion Lung)

LUMC

Open label, fase 1 dosis escalatie (1a) en expansie studie (1b)

A Multicenter, Open-Label Phase 1 Study of Patritumab-Deruxtecan (U3-1402) in Subjects with Metastatic or Unresectable Non-Small Cell Lung Cancer.

Antoni van Leeuwenhoek

Fase 1 studie naar biologische beschikbaarheid van U3-1042 CTM-3. Daarnaast beoordeling veiligheid en verdraagzaamheid.

A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors.

Antoni van Leeuwenhoek

Fase 1 studie naar de veiligheid en verdraagzaamheid van SGN-PDL1V. Dose and schedule optimization and dose expansion.

A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors.

Antoni van Leeuwenhoek

Fase 1 studie naar veiligheid en verdraagzaamheid van monotherapie INCB123667 bij advanced solide tumoren.

A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of MK-1484 as a Monotherapy and in Combination with Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors (MK-1484-001)

Antoni van Leeuwenhoek

Fase 1 studie naar veiligheid en verdraagzaamheid van MK-1484 monotherapie of in combinatie met pembrolizumab. Dosisescalatiestudie.

A Phase 1, Open-label, Multicenter Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MK-4464 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced/Metastatic Solid Tumors (MK-4464-001).

Antoni van Leeuwenhoek

Fase 1 onderzoek naar veiligheid en farmacokinetiek van MK-4464 monotherapie of in combinatie met pembrolizumab.

A Phase 1/2, open label, first-in-human, dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of SAR445877 administered as monotherapy in adults with advanced solid tumors.

Antoni van Leeuwenhoek

Fase 1 / 2 studie naar veiligheid en verdraagzaamheid van SAR445877 en bepalen van maximaal getolereerde dosis van en aanbevolen dosis. Dosisescalatie en dosis expansie cohort.

A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery.

Erasmus MC

This is a randomized, active-controlled, parallel-group, multisite, open-label study of adjuvant pembrolizumab with or without MK-2870 in participants with resectable Stage II to IIIB (N2) NSCLC who did not achieve pCR after receiving neoadjuvant pembrolizumab with platinum-based doublet chemotherapy followed by surgery.

A Phase I Study of Zenocutuzumab (MCLA-128), a Human IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumours (eNRGy trial).

Antoni van Leeuwenhoek

Fase I/II studie naar veiligheid, tolerabiliteit, pharmacokinetiek, immunogeniciteit en anti-tumor activiteit van MCLA-128.

A Phase I study evaluating the safety, tolerability and pharmacokinetics of Tarlatamab (AMG 757) in subject with small cell lung cancer (DeLLphi-300).

Antoni van Leeuwenhoek

A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Sabestomig (AZD7789), an anti-PD-1 and anti-TIM-3 Bispecific Antibody, in Participants with Advanced or Metastatic Solid Tumors.

Antoni van Leeuwenhoek

Een fase I/IIa open-label dosisverhoging en dosisuitbreidingsstudie om de veiligheid, farmacokinetiek, farmacodynamiek en werkzaamheid van AZD7789, een bi-specifiek antilichaam tegen PD-1 en TIM-3, te onderzoeken bij proefpersonen met gevorderde of gemetastaseerde niet kleincellig longkanker.

A Prospective Investigation to Assess the Diagnostic Yield of using a Robotic Navigational Bronchoscopy System with Adjunct Real-time Imaging

Radboud UMC

A prospective, dual-arm, interventional study. Prospective collection of consecutive patients undergoing a biopsy procedure with the Ion Endoluminal system with CBCT imaging, and comparing these results with the prospectively collected cohort of CBCT-navigation bronchoscopy procedures performed at Radboudumc.

A clinical trial of Pembrolizumab (MK-3475) evaluating predictive biomarkers in subjects with advanced solid tumors (KEYNOTE 158).

Antoni van Leeuwenhoek

Evaluatie van voorspellende biomarkers (TMB-H) naar de respons op behandeling met Pembrolizumab.

A first-in-human, open-label, dose escaltion followed by dose expansion phase I/IIa trial to evaluate the safety, prelimenary efficacy and pharmacokinetics of intratumoral CyPep-1 in patients with advanced solid tumors (Catalyst).

Antoni van Leeuwenhoek

Fase I/IIa studie naar veiligheid en verdraagzaamheid van intratumorale toediening van CyPep-1 als monotherapie.

A phase 1/2 first-in-human study of the safety and efficacy of IMC-F106C as a single agent and in combination with checkpoint inhibitors in HLA-A*02:01-positive participants with advanced PRAME-positive cancers.

Antoni van Leeuwenhoek

Fase 1-2 dosisescalatie studie naar monotherapie IMC-F106C of combinatietherapie met checkpoint inhibitor of chemotherapie.

A phase 1/2 study of BMS-986449 with and without Nivolumab in participants with solid tumors.

Antoni van Leeuwenhoek

Fase 1 dosisescalatie studie naar combinatie van BMS-986449 en nivolumab bij gemetastaseerd NSCLC.

A phase Ia/Ib, open-label, multicenter, global, dose-escalation study to evaluate the safety and pharmacokinetics of xmab24306 as a single agent and in combination with atezolizumab in patients with locally advanced or metastatic solid tumors.

Antoni van Leeuwenhoek

Fase 1 studie naar veiligheid, verdraagzaamheid en farmacokinetiek van XmAb24306 monotherapie of combinatie met atezolizumab in cycli van 4 weken.

A phase Ib/II open-label, multi-center dose escalation study of Opnurasib (JDQ443) in patients with advanced solid tumors harboring the KRAS G12C mutation (KontRASt-01)

Antoni van Leeuwenhoek

Fase 1b/2 studie (dosis escalatie en expansie) naar JDQ443 monotherapie en in combinatie met TNO155 na standard of care behandeling

ALKOVE-1

Antoni van Leeuwenhoek

A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)

AMG757 (Amg20200469, DeLLphi-303) Tarlatamab

UMC Groningen

Open Label fase II

ARROS-1

Antoni van Leeuwenhoek and UMC Groningen

a FIH, Phase 1/2, multicenter, open-label, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-520

ARTEMIDE-01

LUMC

Open label, fase 1/ 2 dosis escalatie en expansie studie

AirWaze - Easy and Advanced Tools for CBCT Guided Lung Interventions

Radboud UMC

Primary Purpose: Diagnostic, Interventional Model: Single Group Assignment, Masking: None (Open Label)

Amaze-lung

Antoni van Leeuwenhoek

A multicentre single-arm phase II trial of amivantamab, lazertinib plus bevacizumab in patients with EGFR-mutant advanced NSCLC with progression on previous third-generation EGFR-TKI

Amgen Tarlatamab - Dellphi304

LUMC

Open label, gerandomiseerde fase 3 studie

An open label, Phase I dose escalation trial, with dose confirmation and expansion, of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations (BEAMION-Lung01)

Antoni van Leeuwenhoek and MUMC+

Fase 1 dosisescalatie en dosisexpansie studie met monotherapie BI 1810631.

An open label, first-in-human study of BAY2927088 in participants with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation.

Antoni van Leeuwenhoek and Erasmus MC

Fase 1 studie naar veiligheid en verdraagzaamheid van BAY2927088

An open-label, multi-center, phase I, dose finding study of oral TNO155 in adult patients with advanced solid tumors.

Antoni van Leeuwenhoek

Fase 1 studie naar veiligheid en verdraagzaamheid van TNO155 om tot een aanbevolen dosis en inname schema te komen.

Basket of Baskets: A modular, open-label, phase II, multicentre study to evaluate targeted agents in molecularly selected populations with advanced solid tumour.

Antoni van Leeuwenhoek

Fase 2 studie waarbij in geselecteerde patiëntenpopulatie (voor longkanker MET mutatie/MET CNG ≥6) amivantamab 2 wekelijks gegeven wordt.

CA120-1001

UMC Groningen

CA1201001 is a Phase 1/2, FIH, multi-center, open-label study of oral BMS-986449 administered as a single agent and in combination with nivolumab in participants with advanced solid tumors.

CD137/FAP

Amsterdam UMC

An Open Label, Phase I Dose-finding Study of BI 765179 as Monotherapy and in Combination With Ezabenlimab (BI 754091) in Patients With Advanced Solid Cancers

CIAG933A12101 An open-label, multicenter, Phase I study of oral IAG933 in adult patients with advanced Mesothelioma and other solid tumors.

Erasmus MC

Open label, Phase I, multicenter study, 2 arms with a dose escalation part and a dose expansion part.

CLN-081-001 (REZILIENT1)

Antoni van Leeuwenhoek and LUMC

This is a Phase 1/2, open-label, multicenter, first-in-human trial to evaluate the safety and tolerability, PK, PD, and preliminary efficacy of CLN-081 in patients with locally-advanced or metastatic NSCLC harboring EGFR ex20ins mutations who have previously received platinumbased systemic chemotherapy. Module A of this study is an open-label, randomized, 2-treatment arm crossover food effect PK assessment module.

CodeBreak 202 -AMGEN20190341 Phase 3 studie 1L Sotorasib UMCG

UMC Groningen and MUMC+

Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC)

Amsterdam UMC, Antoni van Leeuwenhoek, Erasmus MC, LUMC, MUMC+, Radboud UMC and UMC Groningen

The ADAPT ALEC trial is a phase IV, RCT in patients with ALK positive NSCLC treated with alectinib. A longer median progression free survival (mPFS) is expected in patients treated with standard dose alectinib when minimum plasma concentrations (Cmin) of alectinib exceed 435 ng/mL.

DIRECT

Amsterdam UMC, DIJKLANDER and OLVG

A single medium-dose radiotherapy, followed by a single dose Durvalumab and surgery for tumor microenvironment modification in early stage NSCLC

DO-2

Erasmus MC

fase 1-studie om de veiligheid en farmacokinetiek van de selectieve MET-kinaseremmer DO-2 te bepalen bij patiënten met gevorderde of refractaire solide tumoren

DS1062-AU304

Amsterdam UMC

A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (Tropion-Lung08) (Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations): TROPION-LUNG08

DeLLphi-305 A phase 3, open-label, multicenter, randomized study of Tarlatamab in combination with Durvalumab vs Durvalumab alone in subjects with extensive-stage small-cell lung cancer following Platinum, Etoposide and durvalumab.

Erasmus MC

Randomized, open-label, multicenter, phase III

Dedication-1 – NVALT 30

Radboud UMC, MUMC+ and Erasmus MC

An open label non-inferiority trial of reduced dose pembrolizumab versus standard of care dose pembrolizumab NSCLC patients who are eligible for treatment with a pembrolizumab-based regimen.

Destiny Lung 04 (D967SC00001)

UMC Groningen

This is a Phase 3, randomized, open-label, 2-arm, multicenter, international study assessing the efficacy and safety of T-DXd compared with SoC (platinum-based chemotherapy with pemetrexed in combination with pembrolizumab) in participants with NSCLC harboring HER2 mutations in exon 19 or 20

Dose tapering and early discontinuation to increase cost-effectiveness of immunotherapy trial number 1

Erasmus MC

An open label randomized non-inferiority study.

Drug Access Protocol (DAP)

Amsterdam UMC, Antoni van Leeuwenhoek, Erasmus MC, UMC Groningen and MUMC+

A Dutch National Protocol to Facilitate Patient Access to Novel Anti-cancer Drugs Awaiting Regulatory Approval or Reimbursement (for met selpercatinib, capmatinib, larotrectinib, entrectinib or tepotinib)

Drug Rediscovery Protocol (DRUP)

Amsterdam UMC, Erasmus MC, UMC Groningen and MUMC+

A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile

ELDAPT

MUMC+

Elderly with locally advanced Lung cancer: Deciding through geriatric Assessment on the oPtimal Treatment strategy

FURMO-004

Antoni van Leeuwenhoek

Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib at 2 dose levels (160 mg and 240 mg) compared to platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic nonsquamous NSCLC with EGFR exon 20 insertion mutations.

GDC-6036 + Pembrolizumab

Antoni van Leeuwenhoek

OPEN-LABEL

GO41596

Amsterdam UMC

A Phase Ia/Ib, Open-Label, Multicenter, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XmAb24306 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors

IMMUCAN

MUMC+

moleculaire profiling van solide tumoren

INCLUSION ON HOLD: RAMP VS-6766-203 A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer

Erasmus MC and LUMC

RAMP VS-6766-203 A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer

INCLUSION ON HOLD: TNO155

Erasmus MC

open-label, multi-center, fase I, dose finding studie met oraal TNO155 in volwassen patienten met gemetastaseerd NSCLC met KRAS G12C mutatie (expansie fase)

IPON-1

MUMC+

Immune profiling of stage III non-small cell lung cancer patients treated with concurrent chemoradiation and adjuvant durvalumab: A prospective observational phase II trial

Libretto-432 J2G-MC-JZXZ

Radboud UMC

Study J2G-MC-JZJX (JZJX) is a randomized, double-blind, Phase 3 study comparing the efficacy and safety of selpercatinib twice daily (BID) to placebo in participants with RET fusion-positive Stage IB-IIIA NSCLC following completion of therapies with a curative intent.

M18-868

MUMC+

Phase 3 Open-Label, Randomized, Controlled, Global Study in Subjects with Previously Treated c-Met+, EGFR Wildtype, Locally Advanced/Metastatic Nsclc ; with Previously Treated c-Met+, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous

M24VUD

Antoni van Leeuwenhoek

Fase 1b/2 studie naar vudalimab in combinatie met chemotherapie of pembrolizumab in combinatie met chemotherapie als eerstelijnsbehandeling bij NSCLC

ML41176-BIO

Antoni van Leeuwenhoek, UMC Groningen and MUMC+

Unraveling tumor response and resistance to combined chemotherapy and PD-L1 inhibition with minimal invasive techniques in patients with advanced NSCLC with targetable disease

MO41552 Randomized, Open label, Multicenter, Phase III study of Entrectinib versus Crizotinib in patients with locally advanced or metastatic Non-Small Cell Lung Cancer harboring ROS1 gene rearrarangements with and without central nervous system metastases.

Antoni van Leeuwenhoek, Erasmus MC and Radboud UMC

Randomized, open-label, multicenter, Phase III trial

MOMENT

LUMC

Prospectieve multi-nationale ziekte registratie studie

NEOpredict

Antoni van Leeuwenhoek

This is an international, multicenter, open-label, randomized, three-armed, modular phase II study. Patients with histologically confirmed non-small cell lung cancer (NSCLC) of clinical stages I B, II and selected stage III A (T3 N1, T4 with satellite nodule in the same lung N0/N1, selected T1a-T2b N2 cases considered suitable for primary surgical approach by the multidisciplinary tumor board), who are eligible for anatomic resection will be included. Subjects in all arms will receive 2 preoperative treatment cycles with a cycle duration of 14 days. Study treatment consists of nivolumab q2w in Arm A, and nivolumab q2w plus relatlimab q2w in Arms B and C.

PAULIEN

Amsterdam UMC

Pembrolizumab alone versus pembrolizumab-chemotherapy in first line NSCLC

POTENTIA

Amsterdam UMC

A Phase 1 Open-Label, Dose Escalation and Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of CB307, a Trispecific Humabody® T-cell Enhancer, in Patients with PSMA+ Advanced and/or Metastatic Solid Tumours

PRT3789-01

LUMC

Open-label, multi-center, first-in-human fase 1 dosis escalatie studie

Phase I, Open-Label Study With Dendritic Cell therapy (MesoPher) In Combination With Extended-Pleurectomy/Decortication After Chemotherapy in Subjects With Resectable Mesothelioma ENSURE (dENdritic cell therapy combined with SURgEry in mesothelioma)

Erasmus MC

This is an open label, single center, phase 1 study

Phase I/Ib study with the combination of RMC-4630 (SHP2 inhibitor) and LY3214996 (ERK inhibitor) in metastatic KRAS mutant CRC, PDAC and NSCLC . SHERPA trial.

Antoni van Leeuwenhoek

Fase 1 studie naar juiste dosering en frequentie van combinatietherapie met RMC-4630 en LY3214996 bij patiënten met KRAS NSCLC.

Phase III Trial of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed vs. Investigator’s Choice of the Standard of Care in Unresectable Pleural Mesothelioma. Evolve-Meso.

Erasmus MC

This is a randomized (1:1), open-label, Phase III trial in participants with untreated unresectable PM evaluating volrustomig (MEDI5752) in combination with carboplatin and pemetrexed compared to investigator’s choice of nivolumab and ipilimumab or platinum plus pemetrexed chemotherapy for participants with epithelioid histology, and nivolumab plus ipilimumab for participants with non-epithelioid histology.

Prediction

LUMC

Prospectief observationeel multicenter studie

RAD-IO study

Antoni van Leeuwenhoek

phase II, multi-center, interventional, non-randomized study

RAMP 203 Verastum

LUMC

Fase 1/ 2 dosis evaluatie en expansie studie

Randomized phase III trial investigating the survival benefit of adding thoracic radiotherapy to durvalumab (MEDI4736) immunotherapy plus chemotherapy in extensive stage small-cell lung cancer

Erasmus MC

International, randomized phase III trial. Patients will be randomized 1:1 stratified for established prognostic factors (presence of brain metastases, and presence of liver metastases) to receive chemoimmunotherapy plus TRT or chemoimmunotherapy alone.

Randomized, Controlled, Open-label, Phase 3, Global MultiCenter Trial to Assess the Efficacy and Safety of Zipalertinib plus Chemotherapy versus Chemotherapy alone, in Patients with Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

Antoni van Leeuwenhoek

Fase 3 multicenter studie naar de effectiviteit en veiligheid van zipalertinib plus chemotherapie versus alleen chemotherapie bij voorheen onbehandeld, lokaal gevorderd of gemetastaseerd NSCLC met EGFR exon-20 insertie-mutatie

SATIN

Amsterdam UMC, Erasmus MC and MUMC+

Safety of TKI concurrent with cranial radiotherapy in NSCLC patients; the SATIN platform trial

SGNB6A-002

Erasmus MC

A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer

SHARP

Amsterdam UMC

A clinical imaging Study of the changes in [18F]F-AraG uptake following anti-PD-1 therapy in Non-small cell lung cancer

SIRP-α

Amsterdam UMC

An open label Phase I PET imaging study to investigate the biodistribution and tumor uptake of [89Zr]Zr-BI 765063 in patients with head and neck squamous cell carcinoma, non-small cell lung cancer or melanoma who are also treated with ezabenlimab

STAR-121 (Gilead GS-US-626-6216)

UMC Groningen and Erasmus MC

Safety and efficacy of a flexible endobronchial sampling instrument that obtains a CORe sample from KeY suspected areas of pulmonary and mediastinal lesions. - COReKeY

Radboud UMC

Open (masking not used), Uncontrolled, Parallel, Diagnostic

TAS6417-301

Amsterdam UMC

Randomized, Controlled, Open-label, Phase 3, Global Multi-Center Trial to Assess the Efficacy and Safety of Zipalertinib plus Chemotherapy versus Chemotherapy alone, in Patients with Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations. (REZILIENT3)

TBPETCT001

Amsterdam UMC

Exploring new imaging opportunities using a large axial field of view PET-CT system

TIGER Meso

Erasmus MC

Non-interventional, observational, prospective, multicentre study on a marketed medical device used in routine clinical care settings following its Instruction For Use within in the approved population

TIL in NSCLC

LUMC

Fase 1 monocenter single-arm interventie studie

TRIDENT-1

Antoni van Leeuwenhoek and UMC Groningen

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 (Repotrectinib) in Patients With Advanced Solid Tumors Harboring ROS1, or NTRK1-3 Rearrangements

The beneficial value of 18F FDG PET/CT in the follow-up of stage III non-small cell lung cancer patients: the NVALT31-PET study

This is a multicenter randomized controlled clinical trial with a superiority design. At approximately 4 months after the end of curative intent treatment patients will be randomized 1:1 to either the intervention (18F FDG PET/CT) or the control group (usual care, CT-based follow-up). Randomization will be done stratifying for histology and treatment.

Amsterdam UMC, Radboud UMC and UMC Utrecht

Tropion-Lung 07

LUMC

Gerandomiseerde fase 3 studie

Tropion-Lung 08

LUMC

Gerandomiseerde, fase 3 studie

UPLAN-1

MUMC+, UMC Groningen

UPFRONT RESECTION OF LOCALLY ADVANCED NSCLC FOLLOWED BY CHEMORADIOTHERAPY (AND ADJUVANT SYSTEMIC TREATMENT); PHASE I MULTICENTER STUDY TO ASSESS TREATMENT FEASIBILITY AND SAFETY (UPLAN-ITRIAL)

USZ-STRIKE

Antoni van Leeuwenhoek

Prospective phase III, multicentre randomised (1:1) open label superiority study

Validation of Rapid On-site Diagnostics in Early Stage Lung Cancer Sampling With a Higher Harmonic Generation Microscope (VALIDIAG)

Radboud UMC

Observational Model: Case-Only, Time Perspective: Prospective, Target Follow-up Duration: 20 Years

eNRGy

Antoni van Leeuwenhoek

This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single indication expansion group assignment study to assess the safety, tolerability, PK, PD, immunogenicity and antitumor activity of MCLA-128. T

eVOLVE-Lung02

Amsterdam UMC

A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).